Higher expression of circulating miR-182 as a novel biomarker for breast cancer

Wang, Pingyu; Gong, Hui; Li, Bao‐Feng; Lv, Chen; Wang, Huan‑Tai; Zhou, Huihui; Li, Xin‐Xin; Xie, Songqiang; Jiang, Baofa

doi:10.3892/ol.2013.1593

Cited by 74 publications

(41 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was also noted in a study on Lebanese FFPE breast cancer tissues [20,31]. miR-182 upregulation was noted in more than one study where its fold change of expression is usually more than 4 folds higher in cancerous breast tissue than in paracancerous tissue [32]. We found that the upregulation of miR-183 and miR-182 were positively correlated.…”

Section: Discussionsupporting

confidence: 85%

miRNA expression in advanced Algerian breast cancer tissues

et al. 2020

View full text Add to dashboard Cite

Breast cancer is one of the commonest cancers among Algerian females. Compared to Western populations, the median age of diagnosis of breast cancer is much lower in Algeria. The objective of this study is to explore the expression of several miRNAs reported to be deregulated in breast cancer. The miRNAs miR-21, miR-125b, miR-100, miR-425-5p, miR-200c, miR-183 and miR-182 were studied on tumor and normal adjacent Algerian breast tissues using quantitative reverse transcription real time PCR, and the results were analyzed according to clinical characteristics. Compared to the normal adjacent tissues, miR-21, miR-183, miR-182, miR-425-5p and miR-200c were found to be upregulated while miR-100 and miR-125b were insignificantly deregulated. A positive correlation was noted among miR-183, miR-182 and miR-200c and among miR-425-5p, miR-183, miR-200c and miR-21. Further global miRNA microarray profiling studies can aid in finding ethnic specific miRNA biomarkers in the Algerian breast cancer population.

show abstract

Section: Discussionsupporting

confidence: 85%

miRNA expression in advanced Algerian breast cancer tissues

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our data in human mammary cell line MCF10A shows that TGFβ inhibits miR-182, and, conversely, TGFβ inhibition increases miR-182, while neither TGFβ addition nor inhibition affects the abundance of miRNAs 146a and 146b (29) or miRNAs 181a and 181b (38), which also target BRCA 1 mRNA for degradation. The amount of miR-182 is increased in breast tumors compared with normal breast tissue (39) and in serum of patients with breast cancer (40). High miR-182 is associated with worse outcome in a meta-analysis of 10 studies (41).…”

Section: Discussionmentioning

confidence: 99%

A TGFβ–miR-182–BRCA1 axis controls the mammary differentiation hierarchy

et al. 2016

View full text Add to dashboard Cite

Maintenance of mammary functional capacity during cycles of proliferation and regression depend on appropriate cell fate decisions of mammary progenitor cells to populate an epithelium consisting of secretory luminal cells and contractile myoepithelial cells. It is well established that transforming growth factor β (TGFβ) restricts mammary epithelial cell proliferation and that sensitivity to TGFβ is decreased in breast cancer. Here we show that TGFβ also exerts control of mammary progenitor self-renewal and lineage commitment decisions by stringent regulation of breast cancer early onset 1 (BRCA1), which controls stem cell self-renewal and lineage commitment. Either genetic depletion of Tgfb1or transient blockade of TGFβ increased self-renewal of mammary progenitor cells in mice and cultured primary mammary epithelial cells, and also skewed lineage commitment towards the myoepithelial fate. TGFβ stabilized the expression of BRCA1 by suppressing miR-182. Ectopic expression of BRCA1 or antagonism of miR-182 in cultured TGFβ-deficient mammary epithelial cells restored lineage commitment. These findings reveal that TGFβ modulation of BRCA1 directs mammary epithelial cell fate and, since stem/progenitor cells are thought to be the cell of origin for aggressive breast cancer subtypes, suggest that TGFβdysregulation during carcinogenesis may promote distinct breast cancer subtypes.

show abstract

“…To date, a large number of genes have been considered to involve in breast cancer. Research has shown that miRNA is directly related to the progression of the disease, having an inverse relationship in cancer patients (11). Oncogenic miR-155 is a well-established miRNA in many tumors, including breast cancer (12) where it can function as an oncogene to affect cancer development (13).…”

Section: Discussionmentioning

confidence: 99%

miR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast

Shooshtarian

Mohammadi-Asl

Kohan

2017

Jentashapir J Helath Res

View full text Add to dashboard Cite

Background: Breast cancer (BC) is an illness affecting millions of women across the world. The transition from ductal carcinoma in situ to invasive ductal breast cancer is a crucial event in the progress that is still not well understood. microRNAs (miRNAs) have recently been documented to play an important role in cancer development. miRNAs have been discovered to control this critical transition. The miR-155 plays an essential role in the pathogenesis of breast cancer. miR-155 has been implicated in developing breast cancer. Objectives: This study aimed to investigate the expression of miR-155 in the serum of patients with breast cancer, according to clinical characteristics (DCIS and IDC) of breast cancer. Methods: 60 patients referring to hospitals in Ahvaz during 2012 and 2015 were divided into 2 groups according to clinical characteristics (DCIS and IDC). miRNA was extracted, and complementary DNA (cDNA) was synthesized in line with the guidelines of the Kit manufacturer. A real-time PCR method was performed as the expression assay. Results: The mean expression level of miR-155 in DCIS group was 6.45 ± 0.545. In addition, the mean expression level of miR-155 in serum of DCI group was 40.42 ± 0.742; the difference was statistically significant (P < 0.0001). Conclusions: Based on the results of this study, the serum level of miR-155 evidenced a statistically significant difference in invasive breast cancer (IDC) patients. The study results showed that checking the serum level of miR-155 expression in patients with invasive breast cancer (IDC) might be helpful.

show abstract

Higher expression of circulating miR-182 as a novel biomarker for breast cancer

Cited by 74 publications

References 38 publications

miRNA expression in advanced Algerian breast cancer tissues

miRNA expression in advanced Algerian breast cancer tissues

A TGFβ–miR-182–BRCA1 axis controls the mammary differentiation hierarchy

miR-155 Expression in the Serum of Patients with Ductal Carcinoma in Situ (DCIS) of the Breast and Patients with Invasive Ductal Carcinoma (IDC) of the Breast

Contact Info

Product

Resources

About